GNFT vs ELVN vs IMVT vs BMY

For growth investors, Genfit S.

A. (GNFT) is the stronger pick with 134. 6% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Genfit S. A. (GNFT) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus Genfit S. A. at 256. 9x.

Over the past 5 years, Genfit S.

A. (GNFT) delivered a total return of +111. 6%, compared to +5. 2% for Bristol-Myers Squibb Company (BMY). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus GNFT's -59. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

50β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 173% more volatile than BMY relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Genfit S.

A. (GNFT) is pulling ahead at 134. 6% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, BMY leads at 1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — GNFT leads at 99. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 67.

2% to $45. 50.

In this comparison, BMY (4.

4% yield) pays a dividend. GNFT, ELVN, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

50), 4. 4% yield). Both have compounded well over 10 years (BMY: +6. 7%, ELVN: -32. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GNFT is a small-cap high-growth stock; ELVN is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; BMY is a mid-cap deep-value stock. BMY pays a dividend while GNFT, ELVN, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.